Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway

Ryuji Ohashi, Takahiko Nakagawa, Susumu Watanabe, John Kanellis, Ramona G Almirez, George F Schreiner, Richard J Johnson

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

p38, a mitogen-activated protein kinase, is a major intracellular signaling molecule involved in inflammation. To test the hypothesis that p38 mediates renal disease progression, we administered a novel p38 inhibitor, NPC31169, to rats with remnant kidneys (RKs). RK rats showed increased p38 activation at 9 weeks (by p38 kinase assay), which was blocked by the inhibitor. In contrast to our expectation, treatment with the NPC31169 resulted in worse renal function, more proteinuria, and more severe glomerulosclerosis and tubulointerstitial injury. p38 inhibition resulted in marked cell proliferation in RK rats, with more proliferating tubular cells, myofibroblasts, and macrophages. In contrast, p38 suppression resulted in less tubular cell apoptosis. Interestingly, Western blot demonstrated increased ERK1/2 phosphorylation in p38-treated rats. No histological changes were observed in p38 inhibited sham-operated rats. Our findings indicate that, whereas blocking p38 usually shows benefit in inflammatory disease, in this model p38 inhibition resulted in accelerated renal progression.We conclude that blocking p38-dependent inflammation may have resulted in enhanced proliferation and increased ERK1/2 activation, and thereby explains the worse renal lesions observed. (Am J Pathol 2004, 164:477a??485)
Original languageEnglish
Pages (from-to)477 - 485
Number of pages9
JournalAmerican Journal of Pathology
Volume164
Issue number2
Publication statusPublished - 2004
Externally publishedYes

Cite this